GlassScriptPhysician profile
Matthew K Kozminski
NPI 1649303108
$151,570.35
in general payments reported to CMS, 2019-2025
64 companies · $437 in 2025
The $437 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $24K · 2021: $40K · 2022: $26K · 2023: $17K · 2024: $9,738 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $6,938 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,587.00 |
| Food and Beverage | $6,937.62 |
| Education | $183.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $40,287.39 | 2019-2024 | Aimovig |
| Abbvie INC. | $36,758.81 | 2021-2025 | |
| Genzyme Corporation | $21,007.13 | 2019-2025 | |
| Allergan, INC. | $19,154.75 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $16,487.65 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $7,543.38 | 2022 | |
| Biogen, INC. | $1,054.05 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $607.85 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $575.10 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Alexion Pharmaceuticals, INC. | $533.14 | 2022-2025 | Ultomiris, Soliris |
| Janssen Pharmaceuticals, INC | $488.70 | 2021-2024 | Xarelto, Ponvory |
| Ucb, INC. | $457.60 | 2019-2024 | Briviact, Nayzilam |
| Lundbeck LLC | $454.27 | 2019-2024 | Vyepti, Rexulti |
| Pfizer INC. | $416.37 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $353.40 | 2020-2023 | Acthar |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Kozminski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.